2. Academic Validation
  3. Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent

Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent

  • Bioorg Med Chem Lett. 2015 Dec 15;25(24):5687-93. doi: 10.1016/j.bmcl.2015.10.098.
Hirofumi Nakano 1,  Tsukasa Hasegawa 1,  Nae Saito 1,  Kaoru Furukawa 2,  Naofumi Mukaida 2,  Hirotatsu Kojima 1,  Takayoshi Okabe 1,  Tetsuo Nagano 3
Affiliations

Affiliations

  • 1 Drug Discovery Initiative, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
  • 2 Division of Molecular Bioregulation, Cancer Microenvironment Research Program, Cancer Research Institute, Kanazawa University, 13-1 Kakuma-machi, Kanazawa, Japan.
  • 3 Drug Discovery Initiative, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. Electronic address: tlong@mol.f.u-tokyo.ac.jp.
PMID: 26547690 DOI: 10.1016/j.bmcl.2015.10.098
Abstract

Serine/threonine kinase PIM3 is a potential therapeutic target for pancreatic Cancer. Here, we describe the evolution of our previous PIM1 Inhibitor 1 into PIM3 Inhibitor 11 guided by use of the crystal structure of PIM1 as a surrogate to provide a basis for rational modification. Compound 11 potently inhibits PIM3 kinase activity, as well as growth of several pancreatic Cancer cell lines. In a mouse xenograft model, 11 inhibited growth of human pancreatic Cancer cell line PCI66 with negligible body weight loss. Thus, 11 appears to be a promising lead compound for further optimization to develop new anti-pancreatic Cancer agents.

Keywords

Anti-cancer agent; Drug design; Kinase inhibitor; PIM3; Pancreatic cancer.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z